Biotech News

Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results

Embecta (EMBC)Embecta2026-06-25 13:46 ESTEarnings

PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported second quarter fiscal 2026 financial results.

Open original release

Related news

Embecta

Embecta is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
Market cap
Exchange
NASDAQ
Sector
Biotechnology
Location
United States